Schizophrenia and co-occurring general medical illness

Psychiatric Annals

Volumn 35, Issue 1, 2005, Pages 71-81

  Cimpean, Delia ^a,c   Torrey, William C ^a   Green, Alan I ^b  

^a Dept Internal Medicine Psychiatry ^*  (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE UPTAKE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ATHEROSCLEROSIS; BODY MASS; CARCINOMA; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; GALLBLADDER; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MENTAL HEALTH CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION RESEARCH; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUDDEN DEATH; VIRUS INFECTION; VITAMIN DEFICIENCY;

EID: 13244257001     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37(9):979-983.
2. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997 Dec;171:502-508.
3. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry. 1999; 60(Suppl 21):10-15.
4. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999;187(8):496-502.
5. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-217.
6. Buda M, Tsuang MT, Fleming JA. Causes of death in DSM-III schizophrenics and other psychotics (atypical group). A comparison with the general population. Arch Gen Psychiatry. 1988;45(3):283-285.
7. Mortensen PB, Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand. 1990;81(4):372-377.
8. Tsuang MT, Woolson RF, Fleming JA. Causes of death in schizophrenia and manic-depression. Br J Psychiatry. 1980;136:239-242.
9. Muck-Jorgensen P, Mors O, Mortensen PB, Ewald H. The schizophrenic patient in the somatic hospital. Acta Psychiatr Scand Suppl. 2000;102(407):96-99.
10. Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999;6(6):287-296.
11. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003;26(1):115-139.
12. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry. 1998;155(11):1490-1501.
13. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29(3):697-701.
14. Adler LE, Griffith JM. Concurrent medical illness in the schizophrenic patient. Epidemiology, diagnosis, and management. Schizophr Res. 1991;4(2):91-107.
15. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
16. Kasper DL, Harrison TR. Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
17. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14): 1723-1727.
18. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res. 2002;55(3):277-284.
19. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
20. McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry. 2003;48(10):689-694.
21. Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol Psychiatry. 1998;43(7):520-524.
22. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997; 58(Suppl 10):45-49.
23. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997; 58(Suppl 10):13-17.
24. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425-433.
25. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002;159(6): 1058-1060.
26. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8): 1334-1349.
27. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry. 2000;22(4):224-235.
28. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-733.
29. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000;45(2):198.
30. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(2):81-85.
31. Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol. 2004;14(4):332-336.
32. Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
33. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
34. Cucuzzella M, Smith PC, Nashelsky J, Spencer DC. When should we treat isolated high triglycerides? J Fam Pract. 2004; 53(2):142-144.
35. Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin Pharmacol Ther. 1985;37(6):684-687.
36. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58(12):1172-1176.
37. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21(4):369-374.
38. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296.
39. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001;62(5):347-349.
40. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy. 2003;23(9):1123-1130.
41. Expert Committee on the Diagnosis and Classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of type 2 diabetes. Diabetes Care. 2003;26(Suppl 1):S5-S20.
42. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000; 26(4):903-912.
43. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63(9):758-762.
44. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-981.
45. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-1711.
46. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002; 14(1):59-64.
47. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59(1):1-6.
48. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891-897.
49. Preventive Cardiology: How can we do better? Proceedings of the 33rd Bethesda Conference. Bethesda, Maryland, USA. December 18, 2001. J Am Coll Cardiol. 2002; 40(4):580-651.
50. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
51. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004; 192(1):19-27.
52. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58(12): 1161-1167.
53. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Inter Med. 2004;164(12): 1293-1297.
54. Coffman JA, Olshansky B, Nasrallah HA, Skorton D, Chapman S. Echocardiographic assessment of schizophrenics and manics: a reexamination of early necropsy findings. J Nerv Ment Dis. 1985;173(3):179-181.
55. Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001;58(9):861-868.
56. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 2000;283(4):506-511.
57. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 2000;22(3): 195-214.
58. Taylor D. Ziprasidone in the management of schizophrenia : the QT interval issue in context. CNS Drugs. 2003;17(6):423-430.
59. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289(16): 2120-2127.
60. Cohen J, Powderly WG. Infectious Diseases. 2nd ed. New York, NY: Mosby; 2004.
61. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am. 1994;23(3):437-455.
62. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91(1):31-37.
63. Carey MP, Carey KB, Kalichman SC. Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses. Clin Psychol Rev. 1997;17(3):271-291.
64. Kalichman SC, Kelly JA, Johnson JR, Bulto M. Factors associated with risk for HIV infection among chronic mentally ill adults. Am J Psychiatry. 1994;151(2):221-227.
65. Moyer LA, Mast EE, Alter MJ. Hepatitis C: Part II. Prevention counseling and medical evaluation. Am Fam Physician. 1999;59(2): 349-354, 357.
66. Brunette MF, Drake RE, Marsh BJ, et al. Responding to blood-borne infections among persons with severe mental illness. Psychiatr Serv. 2003;54(6):860-865.
67. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206-1217.
68. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-965.
69. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18(11): 2316-2326.
70. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry. 2004;161(3): 429-435.
71. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med. 1999;340(17):1370.
72. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun. 2004;18(3):205-213.
73. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
74. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443-451.
75. Gupta S, Masand PS, Kaplan D, Bhandary A, Hendricks S. The relationship between schizophrenia and irritable bowel syndrome (IBS). Schizophr Res. 1997;23(3):265-268.
76. Takahashi KI, Shimizu T, Sugita T, et al. Prevalence of sleep-related respiratory disorders in 101 schizophrenic inpatients. Psychiatry Clin Neurosci. 1998;52(2):229-231.
77. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 2001;58(6): 573-578.
78. Saku M, Tokudome S, Ikeda M, et al. Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. Int J Epidemiol. 1995;24(2): 366-372.
79. Mortensen PB. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand. 1992; 85(5):390-393.
80. Cohen M, Dembling B, Schorling J. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res. 2002;57(2-3):139-146.
81. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317(7156):465-468.
82. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care. 2001;39(8 Suppl 2):II2-45.
83. Schwab B, Drake RE, Burghardt EM. Health care of the chronically mentally ill: the culture broker model. Community Ment Health J. 1988;24(3):174-184.
84. Rosenberg S, Brunette M, Oxman T, et al. The STIRR model of best practices for blood-borne diseases among clients with serious mental illness. Psychiatr Serv. 2004;55(6): 660-664.
85. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.